Medmix AG (XSWX:MEDX) 1-Year Sharpe Ratio: -0.60 (As of Aug. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MEDX Medmix AG XSWX:MEDX
67 GF Score
Price CHF8.93
GF Value CHF8.95
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Medmix AG 1-Year Sharpe Ratio?

Medmix AG XSWX:MEDX +1.25% 67 1-Year Sharpe Ratio is -0.60 as of Aug. 29, 2026. GuruFocus rates XSWX:MEDX with a GF Score™ of 67/100 and a GF Value™ of CHF8.95 (Fairly Valued). The stock has 6 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-29), Medmix AG's 1-Year Sharpe Ratio is -0.60.


Medmix AG  (XSWX:MEDX) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Medmix AG 1-Year Sharpe Ratio Related Terms


XSWX:MEDX vs GEV, ETN, PH: 1-Year Sharpe Ratio Comparison

For the Specialty Industrial Machinery subindustry, Medmix AG's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medmix AG 1-Year Sharpe Ratio vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Medmix AG's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Medmix AG's 1-Year Sharpe Ratio falls into.


XSWX:MEDX
67GF Score
Medmix AG XSWX:MEDX
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medmix AG 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.60 mean?
Medmix AG (XSWX:MEDX) has a 1-Year Sharpe Ratio of -0.60 as of Aug. 29, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Medmix AG and its competitors.
Is Medmix AG's 1-Year Sharpe Ratio too high?
Medmix AG's current 1-Year Sharpe Ratio is -0.60. Overall, Medmix AG has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's 1-Year Sharpe Ratio compare to GEV and ETN?
Medmix AG's 1-Year Sharpe Ratio of -0.60 can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for an Industrial Products company?
A good 1-Year Sharpe Ratio depends on the Industrial Products industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Medmix AG and its competitors. Medmix AG's current 1-Year Sharpe Ratio is -0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Based on GuruFocus' analysis, Medmix AG (XSWX:MEDX) is currently considered Fairly Valued. The stock's GF Value™ is CHF8.95, compared to a current price of CHF8.93 — trading 0.2% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.60. Medmix AG's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Medmix AG (XSWX:MEDX), the current 1-Year Sharpe Ratio is -0.60 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medmix AG (XSWX:MEDX) Overvalued in 2026?

Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued. The current stock price of CHF8.93 is trading 0.2% below its estimated GF Value™ of CHF8.95. GuruFocus considers Medmix AG to be Fairly Valued.

Key valuation signals for XSWX:MEDX:

  • 1-Year Sharpe Ratio: -0.60
  • GF Value™: CHF8.95 vs. price of CHF8.93 (0.2% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the XSWX:MEDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medmix AG Business Description

Other Exchanges MEDXz:UK
Address Neuhofstrasse 20, Baar, CHE, 6340
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
67GF Score

Get the complete analysis for XSWX:MEDX

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF8.93
Price
CHF8.95
GF Value